Insider Trading March 18, 2026

Guidewire CEO Sells $776,194 of Stock as Company Faces Mixed Analyst Views

Rosenbaum disposes of 4,737 shares to cover RSU taxes amid stretched valuation metrics and recent strong quarter

By Avery Klein GWRE
Guidewire CEO Sells $776,194 of Stock as Company Faces Mixed Analyst Views
GWRE

Guidewire Software Inc's Chief Executive Officer, Michael George Rosenbaum, sold 4,737 shares on March 17, 2026, generating $776,194 at $163.8579 per share. The sale, disclosed as a tax-covering move tied to the settlement of Restricted Stock Units, leaves Rosenbaum with 221,206 directly held shares. The transaction comes while the stock has fallen 34% over six months and trades at a price-to-earnings ratio of 73.66. The firm posted a stronger-than-expected fiscal second quarter, raised fiscal 2026 guidance, and recorded 22% year-over-year ARR growth, yet analysts remain divided on valuation and forward multiples.

Key Points

  • Guidewire CEO Michael George Rosenbaum sold 4,737 shares on March 17, 2026, at $163.8579 per share, totaling $776,194.
  • The sale was executed to cover taxes from the settlement of Restricted Stock Units; Rosenbaum now directly owns 221,206 shares.
  • Guidewire reported stronger-than-expected fiscal second-quarter results, raised fiscal 2026 guidance, and recorded 22% year-over-year ARR growth, but analysts differ on valuation and multiples.

Michael George Rosenbaum, Chief Executive Officer of Guidewire Software Inc (NYSE:GWRE), executed a sale of 4,737 common shares on March 17, 2026. The shares were sold at $163.8579 apiece, producing gross proceeds of $776,194. According to the filing, the transaction was carried out to meet tax obligations arising from the settlement of Restricted Stock Units (RSUs). Following this disposition, Rosenbaum's direct ownership stands at 221,206 shares.

The sale occurs against a backdrop of notable price pressure on Guidewire's stock - the share price is down 34% over the prior six months and the company trades at a price-to-earnings multiple of 73.66. An InvestingPro analysis cited in the filing indicates the company appears overvalued relative to its Fair Value, as assessed by that platform.


Operationally, Guidewire reported a robust fiscal second quarter. Total revenue, annual recurring revenue (ARR), and non-GAAP operating income all beat expectations, and management cited increasing momentum and demand in the company's end-market as contributors to the outperformance. Annual recurring revenue expanded 22% year-over-year, a pace described as slightly ahead of consensus estimates.

Following the quarter, Guidewire raised its fiscal 2026 guidance across all reported metrics. Management set targets for both the third quarter and the full fiscal year that exceed consensus estimates, reinforcing the company view on near-term trajectory.


Analyst reaction to the results and guidance has been mixed. DA Davidson retained a Buy rating and left its price target at $246 after the quarter. In contrast, Stifel and RBC Capital reduced their price targets to $250 from $300 - both firms maintained positive ratings but cited software multiple contraction and a valuation review, respectively, as reasons for the downward adjustments. Needham reiterated a Hold rating, explicitly flagging valuation as the central concern.

These developments paint a picture of solid operating performance juxtaposed with valuation apprehension among certain sell-side analysts. The insider sale was disclosed as a tax-driven event tied to RSU settlement rather than a stated change in conviction. The combination of outperformance on quarterly metrics and ongoing analyst scrutiny on multiples results in a mixed market narrative for Guidewire at present.


Note on available analysis - The filing references InvestingPro's assessment indicating the company appears overvalued relative to its Fair Value, with additional insights available through that platform's Pro Research Report.

Risks

  • Valuation risk - The stock trades at a P/E of 73.66 and InvestingPro analysis indicates the company appears overvalued relative to its Fair Value, which may weigh on investor sentiment.
  • Analyst target revisions - Several firms reduced price targets or maintained cautious ratings citing software multiple contraction and valuation review, creating uncertainty around future price discovery.
  • Share-price volatility - The stock has declined 34% over the past six months, indicating potential near-term market volatility that could affect investor returns.

More from Insider Trading

Spyre Therapeutics CFO Disposes $370K in Stock, Exercises Options Same Day as Trial Timelines Accelerate Apr 3, 2026 Fold Holdings CEO completes modest stock sale to cover RSU tax obligations Apr 3, 2026 Spyre Therapeutics CEO Executes $739,912 Stock Sale as Trials Accelerate Apr 3, 2026 Spyre Therapeutics CMO Sells Shares, Exercises Options as Trials Accelerate Apr 3, 2026 Fold CFO Sells Small Stake to Meet Tax Withholding as Company Faces Revenue Shortfall Apr 3, 2026